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Abstract
Background: Generalised anxiety disorder (GAD) is a frequent and severe anxiety disorder among older adults.
GAD increases the risk of developing other disorders such as depression and coronary heart disease. Older adults
with GAD exhibit a poorer response to cognitive behaviour therapy (CBT) compared to younger patients with GAD.
The normal age-related cognitive decline can be a contributor to reduced treatment efficacy. One strategy for
improving treatment efficacy is to combine CBT with adjunctive interventions targeted at improving cognitive
functions. Physical exercise is a viable intervention in this regard. Increased levels of brain-derived neurotrophic
factor may mediate improvement in cognitive function. The present study aims to investigate the proposed effects
and mechanisms related to concomitant physical exercise.
Methods: The sample comprises 70 participants aged 60–75 years, who have GAD. Exclusion criteria comprise
substance abuse and unstable medication; inability to participate in physical exercise; and conditions which
precludes GAD as primary diagnosis. The interventions are individual treatment in the outpatient clinic at the local
psychiatric hospital, with two experimental arms: (1) CBT + physical exercise and (2) CBT + telephone calls. The
primary outcome measure is symptom reduction on the Penn State Worry Questionnaire. Other measures include
questionnaires, clinical interviews, physiological, biological and neuropsychological tests. A subset of 40 participants
will undergo magnetic resonance imaging (MRI). After inclusion, participants undergo baseline testing, and are
subsequently randomized to a treatment condition. Participants attend five sessions of the add-on treatment in the
pre-treatment phase, and move on to interim testing. After interim testing, participants attend 10 sessions of CBT in
parallel with continued add-on treatment. Participants are tested post-intervention within 2 weeks of completing
treatment, with follow-up testing 6 and 12 months later.
Discussion: This study aims to develop better treatment for GAD in older adults. Enhancing treatment response
will be valuable from both individual and societal perspectives, especially taking the aging of the general
population into account.
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Background
GAD is a potentially severe anxiety disorder characterised
by profound and uncontrollable worry that ranges over a
number of events and activities [1]. Patients often have
bodily experiences of restlessness, fatigue and muscle ten-
sion. They often report mood changes such as irritability
and difficulty concentrating, in addition to sleep disturb-
ance. While GAD is a severe and disabling condition in it-
self, it is also associated with an increased risk of comorbid
depression [2]. Furthermore, anxiety disorders in general
are associated with social disability, social isolation, phys-
ical inactivity and reduced quality of life [3–6]. GAD is
highly prevalent in primary care settings, and is present in
22% of patients seeking help for anxiety in this context [7].
The estimates of lifetime prevalence of GAD range from
2.8 to 6.2% [8]. The estimates of prevalence of GAD in
older adults range from 3.2% [9] to 11.5% [10]. In the repli-
cation of the National comorbidity study (NCS-R) by Kess-
ler et al. [11, 12], GAD was estimated to affect 3.6% of
adults above 60 years of age. Byers et al. [9] identified a
12-month 3.2% prevalence of GAD in older adults aged
55–64 years. This differs from the results in the longitu-
dinal LASA study, where GAD was found to be the most
prevalent anxiety disorder among older adults, with rates
(6-month prevalence) ranging from 6.9% in the age group
75–85 years to 11.5% in those aged 65–74 years [10]. The
discrepancies between studies in terms of prevalence could
be influenced by the diagnostic system used. Beekman et
al. [10] used criteria from the Diagnostic and statistical
manual of mental disorders (DSM)-III, while the other
studies have used DSM-IV criteria [9, 11, 12]. However,
Zhang et al. [13] recently investigated the development of
GAD in adults above 65 years of age, and found that more
than 8.4% of this cohort developed GAD across a period of
12 years, in whom 80.0% of cases were of first onset.
Older adults appear to be particularly vulnerable to de-
veloping GAD and a peak in prevalence has been demon-
strated in people aged 50 years and above [14, 15]. The
causes of this peak are so far poorly understood. Ac-
cording to Chou et al. [15], further research is needed
to adress this issue: they point out the presence of
hypertension, poor role functioning, bodily pain, poor
self-rated health status, lack of vitality, poor social
functioning and poor role-emotional functioning in pa-
tients with late-onset GAD. These are, however, only fac-
tors associated with GAD and it is not known if treatment
of GAD will improve these factors or if these factors
contribute to the development in GAD in patients above
50 years of age. LeRoux and colleagues [14] did not find
that experience with negative life events such as widow-
hood, poor health or cognitive impairment was related
to the development of GAD in older adults. They do
however discuss the insensitivity of their measures in
terms of negative life events. Furthermore, they suggest
that disability might be a risk factor for developing
GAD in late life.
Cognitive behaviour therapy (CBT) is the recommended
treatment for GAD [16]. CBT for GAD includes psychoe-
ducation, progressive muscle relaxation, cognitive restruc-
turing and graded exposure [17]. Even though CBT has
generally been found to be more effective as a treatment in
patients with GAD than in control conditions [18], older
adults with GAD are less responsive to treatment than
working-age adults [19, 20]. A recent meta-analysis identi-
fied lower effect sizes in older compared to working-age
adults with GAD [21]. Several studies have attempted to
improve the treatment efficacy in older adults with GAD,
with promising results.
Wetherell and colleagues investigated the effects of
combined antidepressant medication (escitalopram) with
CBT, compared to escitalopram alone [22]. The partici-
pants first received acute treatment with escitalopram,
followed by 16 weeks of either escitalopram alone or
escitalopram + CBT, and a maintenance phase of 28 weeks
with continued escitalopram. The CBT consisted of 16
sessions, and trained therapists delivered the CBT accord-
ing to a manual. The combined CBT and escitalopram
group had a significantly lower score on the Penn State
Worry Questionnaire (PSWQ) following maintenance
treatment, as compared to the escitalopram group alone
[22]. The PSWQ is a self-report measure of worry severity,
and a larger reduction in scores indicates a larger change
in the respondent’s experience of worry severity [23]. The
authors conclude that CBT can in fact augment the effect
of medical treatment for GAD, and that both escitalo-
pram and CBT can provide relapse prevention bene-
fits. However, they also point out the limitations of
the small sample size and lack of long-term follow up
after the maintenance treatment phase.
Several authors suggest that the age-related cognitive
decline, and especially a reduction in executive functions,
could be an important mediator of the poorer treatment
efficacy of CBT in older adults [24–26]. The cognitive
functions most often affected by normal aging reflect
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executive performance, such as the ability to organize and
plan activities, shift and direct attention and adjust behav-
iour according to long-term goals [27]. Consequently,
some studies on augmenting the treatment of GAD in
older adults have focused on add-on strategies designed to
improve cognitive functions. Mohlman and colleagues
published an article in 2003 on two pilot studies investi-
gating the effects of standard and enhanced CBT for treat-
ment of GAD in older adults, as compared to a wait-list
condition [28]. Both the standard and enhanced CBT were
based on the same treatment manual (13 weekly individ-
ual 50-min sessions). The enhanced CBT, however, add-
itionally included learning and memory aids, which aimed
to increase homework compliance, strengthen the mem-
ory of skills learned in treatment and facilitate the use of
these skills. Participants receiving enhanced CBT were
more homework-compliant than participants receiving
standard CBT, and the treatment effect sizes were
somewhat larger with enhanced than with standard
CBT. The authors note that improvements in both
groups were modest compared to effect sizes seen in
younger samples, and suggest further investigations of
the effectiveness of add-on strategies with CBT in
older adults with GAD [28].
Mohlman and Gorman [24] conducted a pilot study
whereby 32 adults aged 60 years or older received 13
individual weekly CBT sessions according to a published
protocol, and 6-monthly booster sessions for 6 months
consecutively. Participants underwent neuropsychological
testing to examine executive function, and the authors ini-
tially categorized participants with either intact executive
function, or executive dysfunction. However, a subset of
the participants with executive dysfunction had improve-
ments in executive functioning at the post-treatment
neuropsychological assessment, and the authors thus cate-
gorized them as having improved executive function. The
participants with intact and improved executive function
improved the most in the treatment outcome measures
post treatment and at follow up, whereas the participants
with executive dysfunction neither improved in execu-
tive function nor in the outcome measures. The authors
conclude that baseline executive dysfunction is not a
clear predictor of treatment outcome in their study.
However, their findings also implicate that in a subset
of participants, executive dysfunction is associated with
non-response to CBT [24].
One small pilot study has investigated whether an ex-
ecutive skills rehabilitation programme could augment the
treatment efficacy of CBT in older adults with GAD [25].
Eight older adults received either CBT (13 weekly individ-
ual 50-min sessions) or CBT combined with executive
skills training. The participants in the CBT + executive
skill training condition had significantly better improve-
ment on the PSWQ than the participants receiving
standard CBT. The small sample size clearly limits the
generalisability of the results, but points to targeting
executive functions as a viable add-on strategy to im-
prove the outcome of CBT in older adults with GAD.
In summary, the pilot studies on add-on strategies fo-
cusing on improving cognitive function all suggest that
add-on strategies targeting age-related cognitive decline
can be a viable approach in improving treatment efficacy
in older adults with GAD, and recommend future research
to systematically further examine the use of add-on inter-
ventions adjunct to CBT. Another suggested approach
aimed at improving executive function is to include phys-
ical exercise as a part of the treatment programme [29].
Engaging in physical exercise over time has several
demonstrated benefits, such as improved cognitive func-
tion and increased brain volume in the prefrontal and
temporal cortices [30, 31] and preservation of hippo-
campal volume in older adults [32]. Physical fitness level
is positively related to cognitive function, especially execu-
tive function, and to preservation of brain tissue [33, 34]. It
has further been shown that aerobic exercise can increase
the plasticity of the brain and this increase is associated
with improved cognitive function [35]. A mechanism in-
volved in the increased plasticity is the neurotrophin
brain-derived neurotropic factor (BDNF) [36]. Improved
cognitive function has been shown to be mediated by in-
creased BDNF [37, 38]. BDNF protects the brain against
the harmful effects of stress through support of neuronal
plasticity, synaptogenesis, synaptic efficacy and neuronal
survival [39]. BDNF decreases as a function of stress and is
reduced in both anxious and depressed patients [40, 41],
and increased in both healthy, depressed and anxious pa-
tients after physical exercise [40, 42]. Furthermore, BDNF
levels relate to the effects of exposure-based interventions.
The level of BDNF in the brain has been related to suc-
cessful fear extinction [43], and peripheral BDNF has
been shown to be positively related to the effectiveness
of exposure-based treatment for post-traumatic stress
disorder (PTSD) [44] and panic disorder [45].
Physical exercise is known to positively affect not only
cognitive functions, but also cardiac regulation [46, 47], in-
cluding heart rate variability (HRV). HRV is a predictor of
all-cause mortality and death following myocardial infarc-
tion [48, 49]. Patients with anxiety disorders have reduced
HRV [50], which is considered to result from altered in-
hibitory activity in the prefrontal cortex (PFC) [51]. Execu-
tive function and HRV have been found to be related both
in healthy adults [52, 53] and in patients with anxiety [54].
Though HRV decreases with increasing age [55], it was re-
cently demonstrated that physical exercise could increase
HRV in healthy older adults [56] and that changes in HRV
are related to the performance of physical exercise.
Previous studies investigating long-term physical exer-
cise as an adjunct to with CBT for treatment of anxiety
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disorders have shown mixed results. One study had null
findings [57], two studies indicate benefits of adjunct
physical exercise [58, 59] and one feasibility study con-
cluded that add-on physical exercise is feasible and po-
tentially beneficial [60]. The study that did not find
positive effects of CBT combined with physical exercise
was in a non-clinical sample [57], which suggest a lim-
ited added effect of physical exercise in a non-clinical
population. A recent study on physical exercise combined
with exposure therapy for panic disorder demonstrated
the lack of a significant effect of adjunct physical exercise.
The authors point to ceiling effects as the reason for the
lack of effect of the add-on treatment, as exposure therapy
already has high treatment efficacy [61]. This is in line
with a point made by other authors, that physical exercise
could be a more potent intervention in groups in whom
treatment with CBT has limited effects (e.g. [62]).
Based on this rationale, the aim of the present study is
to compare the effects of physical-exercise-augmented
CBT to standard CBT combined with a placebo control
condition. We expect that exercise-augmented CBT will
yield better results than standard CBT as measured by
our primary outcome measure, symptom reduction on
the Penn State Worry Questionnaire (PSWQ) [23]. The
proportion of patients who achieve remission as assessed
by an independent clinical assessor using the Anxiety Dis-
orders Interview Schedule for DSM-IV (ADIS-IV) [63], will
be assessed as a secondary outcome measure. We also ex-
pect levels of BDNF at baseline to be positively related to
treatment outcome, and that the participants that receive
augmented CBT will improve significantly in the cognitive
measures and in levels of BDNF following treatment as
compared to the CBT alone group. Furthermore, we expect
HRV to improve with exercise-augmented CBT, and
that these changes will correlate with clinical change,
and changes in cognitive functions and BDNF levels.
Method
Study design
The study is a 2 × 2 mixed factorial design (Time x Group)
with participants randomized to one of two treatment con-
ditions: (1) CBT combined with physical exercise (CBT+
PE) or (2) CBT combined with telephone call attention
placebo (CBT+AP). Participants complete pre-treatment,
interim and post-treatment outcome measures, in addition
to follow-up tests at 6 and 12months after treatment.
Participants in both treatment conditions attend a
5-week pre-treatment period. The pre-treatment period
has a two-part rationale. The first 5 weeks of physical
exercise are aimed at introducing the participant to the
exercises with a focus on adjustment and neuromuscular
facilitation [64]. In addition, resting BDNF has been shown
to increase after 5 weeks of physical exercise [65]. The pri-
mary goal of the pre-treatment period is to ensure good
implementation of physical exercise, and to obtain elevated
resting BDNF in the CBT + PE group before the onset of
CBT. As such, the pre-treatment period is a measure to
facilitate the add-on effects of physical exercise.
Participants receiving CBT + PE attend one supervised
and two unsupervised sessions of PE during each of the 5
weeks of the pre-treatment period. Participants receiving
CBT +AP receive one telephone call per week during the
pre-treatment period.
After the pre-treatment period, the participants receive
10 weekly sessions of CBT combined with either contin-
ued physical exercise in the participants receiving CBT +
PE or weekly telephone contact in parallel to the CBT
sessions in the participants receiving CBT +AP. See Fig. 1
for a display of the study design. The present protocol has
been prepared in accordance with relevant items from the
Standard Protocol Items: Recommentations for Interven-
tional Trials (SPIRIT) Checklist (see Additional file 1). See
Fig. 2 for the SPIRIT figure displaying the schedule of en-
rolment, interventions and assessments.
Participants
Adults, aged 60–75 years (n = 70), who have a primary
diagnosis of GAD as evaluated by the ADIS-IV [63] will
be included. Exclusion criteria are (1) substance abuse;
(2) use of benzodiazepines and antipsychotic medication;
(3) changes in the dose of other psychotropic medication
during the study; (4) medical conditions that preclude
participation in physical exercise; (5) severe major depres-
sion as determined by the Mini International Neuropsychi-
atric Interview (M.I.N.I.) [66, 67]; (6) life-time history of
psychosis and/or mania; (7) participation in other ongoing
psychotherapy; (8) organic brain disease; (9) a score of 25
or less on the Mini Mental State Examination (MMS-E)
[68] and (10) participation in physical exercise exceeding
75% of the exercise dose given in the study.
A subsample of 40 participants, who do not the meet
exclusion criteria for magnetic resonance imaging (MRI),
will be included in a nested MRI study. The exclusion
criteria for MRI are (1) MRI-incompatible metal screws or
implants; (2) large tattoos on head, neck or upper
body; (3) pacemaker and (4) claustrophobic fear, to a
degree whereby participants refuse to undergo MRI
without sedatives. These exclusion criteria are applied
to ensure patient safety.
Measures
Clinical interviews
During the diagnostic work before inclusion, we use the
M.I.N.I. [66, 67] to determine comorbid psychiatric condi-
tions and the ADIS-IV [63] to determine the presence of
GAD. After treatment, an independent assessor determines
remission from GAD using the ADIS-IV [63].
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Questionnaires
The PSWQ [23] assesses the severity of symptoms in
GAD. This is a 16-item self-report questionnaire whereby
participants rate each item on a scale from 1 (not at all
typical of me) to 5 (very typical of me). A higher score indi-
cates a high level of worry. Five items are reverse-scored.
The Beck Anxiety Inventory [69] assesses general anxiety.
This is a 21-item self-report questionnaire whereby partici-
pants rate each item on a 0–3 scale, where 0 is “Not at all”
and 3 is “Severely – it bothered me a lot”. The Beck De-
pression Inventory – II [70] measures the level of depres-
sion. This is a 21-item self-report questionnaire whereby
each item is scored on a 0–3 scale. A higher score indicates
greater symptom severity. The Generalized Anxiety Dis-
order Questionnaire [71] is a screening tool for GAD, and
will be used as a session-by-session assessment and at each
data collection point. This is a 7-item self-report question-
naire whereby participants rate themselves on a scale from
0 (not at all sure) to 3 (nearly every day). A higher score
indicates greater symptom severity. The Geriatric Anxiety
Inventory [72] measures general anxiety in older adults.
This is a 20-item self-report questionnaire with “Agree/
Disagree” categories. Agree is scored 1 and disagree 0, and
a higher score indicates greater anxiety. Symptoms of in-
somnia will be assessed by the Bergen Insomnia Scale [73].
This is a 6-item self-report questionnaire whereby partici-
pants rate themselves on a scale from 0 to 7, indicating the
number of days they report the problem. A higher score
indicates more symptoms of insomnia. The Quality of
Life Inventory [74] will be used to assess quality of life.
This is a 32-item self-report questionnaire assessing di-
verse aspects of quality of life, such as “Health”, “Econ-
omy”, “Creativity” and “Love”. Each category is evaluated
both by how important it is to the participant (from 1
(not important) to 3 (very important)) and by how sat-
isfied they are with it (from − 3 (very dissatisfied) to 3
(very satisfied)). The Credibility/Expectancy Question-
naire [54] measures treatment expectancy. This is a
5-item self-report questionnaire whereby participants
rate statements about treatment on a scale from 1 to
10, where a higher score indicates greater credibility. In
addition, participants complete the International Phys-
ical Activity Questionnaire (IPAQ-short) [75, 76] to as-
sess physical activity level. This is an 8-item self-report
questionnaire, whereby the participant indicates how
much time he or she has spent on high and moderate
intensity physical activity, walking and sitting during
the last 7 days.
We expect participants to spend 45–60min complet-
ing the questionnaires at each test point. To avoid miss-
ing data, the participants complete the questionnaires
with one of the project coordinators present. As such,
participants can ask questions about the questionnaires,
and the project coordinator can ensure that the partici-
pant has answered all questions.
Neuropsychological testing
IQ level will be assessed with two subtests, Vocabulary and
Matrix Reasoning, from the Wechsler Abbreviated Scale of
Intelligence [77]. Psychomotor speed and hand-eye coord-
ination will be measured using the Grooved Pegboard Test
[78], and the subtest, Coding, from the Wechsler Adult
Intelligence Scale – Fourth Edition [79]. Executive
functions will be assessed using the Wisconsin Card
Sorting Test: Computer Version 4 research edition [80],
alongside three subtests from Delis-Kaplan Executive
Fig. 1 Study design. Visual presentation of the study design, including sample, assessments, and interventions. GAD, generalised anxiety disorder;
CBT, cognitive behaviour therapy
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Fig. 2 (See legend on next page.)
Stavestrand et al. Trials          (2019) 20:174 Page 6 of 14
Function System battery [81]: Trail Making Test, the Verbal
Fluency Test, and the Color-Word Interference Test, and
working memory is assessed using the subtest, Numbers,
from the WAIS-IV [79]. Verbal memory will be measured
using the California Verbal Learning Test [82].
Physiological and biological measures
Serum BDNF is measured in blood samples and assayed
using the Human proBDNF and mBDNF DuoSets [83, 84].
We use an ambulatory electrocardiogram (ECG) [85]
to measure HRV. Physical fitness is measured by the
Ekblom-Bak submaximal cycle ergometer test [86], the
Five-Minute Pyramid Test [87] is used for prediction
of maximal oxygen uptake (VO2 max) and items from
the Senior Fitness Test are used for measuring sub-
maximal physical strength [88].
The study will investigate potential mediators and mod-
erators of treatment outcome. Cortisol is measured in
three saliva samples collected during the assessment days,
and is analysed using the cortisol saliva luminescence im-
munoassay [89]. Genetic material is obtained by one saliva
sample at baseline, and analysed using the TaqMan method
[90]. Participants wear the Philips Actiwatch 2 [91] for 1
week at baseline, post-intervention and at 12-month follow
up to measure activity level and sleep variables.
A subsample of 40 participants undergo MRI at baseline,
post testing and at 12-month follow-up testing. MRI will be
performed using a GE Signa 3 .0T twin speed HDxt scanner
[92]. A head coil with video goggles allows for the Eriksen
flanker task [93] to be applied during functional MRI.
Procedures
This study will be conducted at an outpatient clinic at
Solli DPS, a local mental health facility. The neuro-
psychological testing and MRI will take place at
Haukeland University Hospital, in cooperation with
the University of Bergen. There are five test points for
each participant: baseline, interim, post-treatment and
6-month and 12-month follow up. We have designed
the pattern of test points for the investigation both of
treatment mechanisms and treatment outcome.
Baseline testing
The baseline testing consists of several elements: (1) a
start-up conversation with a project coordinator, whereby
the participant completes questionnaires, receives saliva
samplers with instructions and receives an actigraph
watch; (2) a physical/physiological test day, when the
participants undergo ECG, provide a saliva sample for
DNA testing and blood samples for measurement of
BDNF and undergo tests of physical fitness and strength;
(3) an appointment for neuropsychological testing and (4)
an appointment for functional magnetic resonance im-
aging (fMRI).
Randomisation
Randomisation is performed anonymously at the University
of Bergen in blocks of ten following baseline testing. Ran-
domisation is computerised and concealed [94]. The person
conducting the randomisation is blind to participants’ iden-
tities and does not have any information on the partici-
pants. Blocks of ten were preferred, to achieve predictability
for the hospital and staff. This does, however, mean that for
every block, the tenth allocation can be determined with
certainty if that of the former nine is tracked. Calculations
using hypergeometric distributions also show that there is a
4.76%, 16.66% and 44.44% probability that the precise allo-
cation of participants can be known with certainty follow-
ing 6, 7 and 8 draws respectively. However, information
about allocation is not tracked, and was deemed an accept-
able risk to achieve practical feasibility of running the trial
within a clinical setting.
Blinding
This study is single-blinded. We do not disclose to the
participants which of the adjunct interventions we ex-
pect to be the active intervention. Patients are informed
that we investigate two adjunct strategies, and that we
will evaluate which of these provides better treatment effi-
cacy. We take great care to inform all involved personnel
to convey this message.
The independent clinical assessor, who evaluates remis-
sion after treatment, does not know which adjunct inter-
vention the participant received during treatment. The
appointment with the independent clinical assessor is
scheduled without giving the assessor access to the pa-
tient’s medical journal. Also, the project coordinator meets
with each patient before the appointment and give instruc-
tions not to reveal treatment allocation. After the inter-
view, we ask the independent clinical assessor whether the
patient revealed treatment allocation, and make a record of
the response.
(See figure on previous page.)
Fig. 2 Standard protocol items: recommendation for interventional trials (SPIRIT) figure. Schedule of enrolment, interventions and assessments.
Overview of the measures applied in the study. CBT, cognitive behaviour therapy; ADIS-IV, Anxiety Disorders Interview Schedule for DSM-IV;
M.I.N.I., Mini International Neuropsychiatric Interview; PSWQ, Penn State Worry Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale;
IPAQ, International Physical Activity Questionnaire; HRV, heart rate variability; BDNF, brain-derived neurotropic factor; WASI, Wechsler Abbreviated
Scale of Intelligence; WAIS-IV, Wechsler Adult Intelligence Scale – Fourth Edition; D-KEFS, Delis–Kaplan Executive Function System; TMT, Trail-
Making Test; VF, Verbal Fluency; CWIT, Color Word Interference Test
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Pre-treatment period
After randomization, the included participants go on to
the pre-treatment period with either five weekly sessions
of physical exercise or telephone call attention placebo.
The pre-treatment period lasts 5 weeks, but can be
extended by 2 weeks due e.g. to illness or holidays. If
after the maximum extension period the patient has
completed fewer than five sessions, the patient proceeds
to interim testing. Compliance will be registered for each
participant.
Interim testing
The interim testing consists of two appointments; a
physical/physiological test day, in which participants
undergo ECG, provide blood samples for measurement
of BDNF, test physical fitness and strength, and are pro-
vided with take-home saliva samplers; and an appoint-
ment with a project coordinator, whereby the participant
completes questionnaires and returns the saliva
samplers.
Treatment
After interim testing, participants have a start-up conver-
sation with their CBT therapist, followed by 10 weekly
sessions of CBT combined with either physical exercise or
telephone call attention placebo. The treatment period
lasts approximately 11 weeks, but can be extended by 4
weeks due e.g. to illness or holidays. Interventions are
scheduled on separate days of the week, so that the par-
ticipant does not attend both CBT and supervised physical
exercise on the same day. We register compliance for each
participant.
Post-treatment testing
Post-treatment testing starts as soon as possible after
completion of treatment, and no later than 2 weeks after
the last treatment session. The post-treatment testing
corresponds to the baseline testing, with the exception of
the DNA saliva sample, which is only provided at baseline.
Follow-up testing at 6 months
The 6-month testing corresponds to the interim testing.
Follow-up testing at 12 months
The 12-month testing corresponds to the post-treatment
testing.
Interventions
Cognitive behaviour therapy (CBT)
Participants attend 10 sessions of individual CBT applied
following a manual, in accordance with the protocol de-
veloped by Borkovec [17]. One initial session focuses on
developing a therapeutic alliance and introducing the
therapy before the CBT is applied. The duration of the
CBT is approximately 10 weeks. The therapist and partici-
pant can agree to increase the number of weeks within rea-
sonable limits, or do more than one session within one
week, in case a participant misses one or more CBT ses-
sions (e.g. because of holidays, illness, etc.). If the duration
of the therapy exceeds 15 weeks, the participant will not re-
ceive the remaining sessions. The project coordinators
keep a record of the number of CBT sessions each partici-
pant attends. We have adapted the CBT manual to the
study in collaboration with Professor Hans M. Nordahl
from the Norwegian University of Science and Technology.
Professor Nordahl also provides training and supervision
to the therapists who perform CBT, who are psychologists
or psychiatrists with formal training in CBT and specific
education in the study CBT manual. Before treating partic-
ipants in the PEXACOG study, therapists are required to
have performed one full video-documented therapy that
has been rated by an external assessor and scored on the
Cognitive Therapy Adherence and Competence Scale
(CTACS) [95] with a mean score of 3 or higher. Two quali-
fied assessors will evaluate at least 20% of the individual
therapists’ treatment courses according to the following
procedure: Therapists record all CBT sessions. The re-
corded sessions will be drawn randomly, stratified by first
or second half of the treatment course (i.e. session 1–5 or
6–10). Both assessors will rate each selected recording on
the covered domains in the CTACS, and CTACS ratings
are compared to determine inter-rater reliability.
The CBT consists of several elements. Participants re-
ceive psychoeducation about anxiety and the treatment
model. They also learn diaphragmatic breathing, and
two versions of a progressive muscle relaxation exercise
- one longer version with 7 muscle groups, and one
shorter version with 4 muscle groups. These elements
receive attention throughout the treatment. Participants
complete homework assignments between sessions, in-
cluding daily registration of anxiety level. Participants re-
ceive an mp3 player with recorded instructions on
diaphragmatic breathing and progressive muscle relax-
ation to use between sessions. Furthermore, participants
learn cognitive monitoring and restructuring. A key
element of the CBT is self-controlled desensitisation.
Self-controlled desensitisation is a process whereby par-
ticipants establish an anxiety hierarchy, learn new re-
sponses to anxiety cues, and connect the anxiety cues
with the new response. To practice self-controlled de-
sensitisation, participants are asked to worry on purpose,
and respond with relaxation when the anxiety levels are
elevated. The final treatment session focuses on relapse
prevention.
Physical exercise (PE)
The duration of the PE programme is 15 weeks. The first
5 weeks comprise the pre-treatment intervention. During
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the following 10 weeks the participants attend to both PE
and CBT. Each week consist of one supervised training
session at the local mental health facility (clinic), and two
individual training sessions. Supervised sessions are led by
physiotherapists or occupational therapist who are trained
in the study manual and receive supervision on test proce-
dures and the exercise manual. For the individual training
sessions, each participant is given their own exercise jour-
nal with instructions, and is instructed to log each individ-
ual training session. All participants use a heart rate
monitor watch [96], which is used during individual en-
durance training sessions and monitored by the PE ther-
apist at the supervised training session. This is a measure
of patient adherence to the PE. Physical tests at the
interim and post testing time points also serve as manipu-
lation checks. The participants complete the GAD-7 ques-
tionnaire at each of the supervised training sessions.
The PE programme is adjustable according to the par-
ticipants’ prerequisites, without compromising the exer-
cise intensity. Each session lasts approximately 45–60
min, and contains both strength and endurance training.
The strength training programme consists of seven exer-
cises; squats, push-ups, lunges, rowing with elastic
bands, calf raises, dips and shrugs with elastic bands. En-
durance training is designed based on interval principles.
The exercise intensity progresses every fifth week. The
intensity level at the beginning of the intervention
period (week 1–5) will be low to moderate (65–85% of
maximum heart rate (HR max)). It increases to moder-
ate intensity at week 6–10 (65–90% of HRmax) and at
week 11–15 it increases to moderate to high intensity
(65–95% of HRmax). This equals 60–70%, 70–80% and
80–90% of one repetition maximum (1RM) [97] when
transferred to resistance load in strength exercises [98].
The exercise programme is designed to ensure that par-
ticipants take part in at least the minimal therapeutic
dose of exercise, which is 150 min of moderate intensity
activity per week [99, 100].
Telephone call attention placebo
The telephone call attention placebo lasts 15 weeks, with
one telephone call scheduled each week. PhD candidates,
who are trained clinical psychologists, conduct the tele-
phone calls. The telephone contact has no treatment
intention, and will follow an interview guide with the ques-
tionnaire GAD-7 and talking points such as “How was your
week?” and “Do you have any plans for the week-end?”.
Each call lasts no longer than 20min. The intention of the
telephone call attention placebo is to control for the extra
therapist contact in the physical exercise condition, and to
ensure that participants spend approximately the same net
amount of time in direct therapist contact across the treat-
ments. The first 5 weeks of telephone call attention placebo
is an initial phase of treatment. During the following 10
weeks, telephone calls are combined with CBT.
Recruitment and eligibility
We will recruit participants through primary health care
services and the media. Assessment for the trial requires
a formal referral from a primary physician to the hos-
pital. The project coordinators apply the following inter-
views with potentially eligible participants: the M.I.N.I.
[66, 67], the GAD-module from ADIS-IV [63] and the
MMS-E [68]. If eligible for inclusion, participants sign
an informed consent form, and complete self-report
baseline measures. Furthermore, the project coordina-
tors obtain written approval for participation from the
participants’ primary physician to ensure their safety in
participating in physical testing and exercise. The project
coordinators schedule baseline testing once the primary
physician has medically cleared the participant.
Data management and security
Each potential participant is assigned a unique identifica-
tion number at the start of the assessment. Only the project
coordinators have access to the connecting key, which we
store at a separate domain on a secure research server. We
handle all data according to internal procedures, and store
data on the hospital regional secure research server. We
store biological material in a research-specific biobank in
accordance with the Regional Committee for Medical and
Health Research Ethics procedures. We will anonymize all
data 5 years after trial completion.
Ethical considerations
The participants meet several persons during assess-
ment, testing and treatment. Thus, to create predictabil-
ity, continuity and safety, each participant is allocated a
project coordinator who is responsible for their clinical
pathway. Challenges and adverse events during treat-
ment are handled by the project coordinator according
to internal procedures. The project coordinator also has
a closing conversation with the patient at the end of
treatment to inform participants about follow-up testing
and give them the opportunity to give feedback on treat-
ment and research participation. The assessments at
each test point in the study are allocated across several
days to minimise strain on participants.
The development of cognitive impairment can be-
come evident during the assessment phase. This can
cause participants stress and potentially aggravate psy-
chiatric symptoms. In cases where we document cog-
nitive impairment during the initial assessment, the
project coordinator excludes the participant from fur-
ther participation. The project coordinator offers to
refer the participant to gerontopsychiatric services.
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If conditions that exclude patients from participating in
the study are disclosed or develop during treatment, the
participant will be discontinued from trial participation. In
such cases, the participant will continue treatment or be
referred for other suitable treatment, depending on the
reason for discontinuing trial participation. If patients are
in acute need of further treatment following ordinary trial
termination, they are offered services as necessary at Solli
DPS or other suitable facilities. All participants are insured
through The Norwegian Patient Injury Compensation.
We conducted a feasibility study of four participants
who received CBT + PE in March 2016 to August 2017.
One of the ethical arguments for conducting the feasibil-
ity study was to ensure that the total load of testing and
treatment was within the limits that the participants
could tolerate. We also wanted to test the coordination
of testing and treatment. Results from the feasibility
study have been presented at two conferences. Further,
we presented preliminary results and our experiences
with the implementation of the physical exercise proto-
col at the 7th International Conference of Physiotherapy
in Psychiatry and Mental Health in Reykjavik [101]. We
presented the feasibility study and results at the 48th
Annual Congress of the European Association for Be-
havioural and Cognitive Therapies [102]. Our conclu-
sions from the feasibility study are that the combination
of physical exercise and CBT appears to be feasible and
potentially beneficial in our target population.
Power analysis and statistical analysis
Power estimates were calculated using the G* Power 3
programme [103]. Treatment effects will be investigated
by an intention-to-treat approach to data analysis using
a hierarchical linear model, whereby therapists will be
included at the second level to account for potential
nesting by this factor. Power analysis for effects are esti-
mated with conservative repeated measures analysis of
variance (ANOVA) (within-between interactions). For
the primary outcome measure, based on previous studies
[22, 28], the difference in effect size is set to d = 0.35,
alpha = 0.05, correlation between repeated measures 0.5,
two measurements (pre/post), a total of 70 subjects (n = 35
in each group) yielding power above 0.82. Moderators and
mediators will be investigated using linear multiple regres-
sion, fixed model, single coefficients. An effect size set to
f2 = 0.15, two-tailed tests, alpha = 0.05 and N = 70 yields
power above 0.95 with four predictors. For the subset of
functional MRI (fMRI) assessments the following statistics
and power analysis will be applied: task-fMRI data will be
analysed using General Linear Model in SPM12 for
pre-processing and single subject and group analyses,
GIFT [104] to investigate the functional and structural
data, and arterial spin labelling (ASL) data will be analysed
in SPM12. Region of interest (ROI) will be analysed for
both structural and functional data (SPM12) to extract
blood oxygen level dependent (BOLD) responses to test
correlation with specified variables. Expecting percent sig-
nal changes of approximately 0.5% at the single voxel and
spatial smoothing at full width at half maximum (FWHM)
of 5mm (provides an estimated effect size of d = 0,7), using
the two-tailed independent samples t test, an allocation
rate of 1, alpha set to 0.05, correlation between repeated
measures 0.5 and a total sample size of 80 (40 in each
group) yields power above 0.87. For differences between
pre-treatment and post treatment data using the same pa-
rameters, the matched-pairs t test with 20 subjects yields
power above 0.90. Treatment effects are estimated using
conservative repeated measures ANOVA (within-between
interaction), and conservatively setting the estimated value
of d = 0.35, alpha set to 0.05, two measurements (pre, post),
correlation between repeated measures 0.5, and 60 subjects
(n = 20 per group) yields power above 0.83. Based on these
calculations, the estimated power values indicate that risk
of committing type II errors is adequately controlled.
To control for type 1 errors, the secondary clinical
outcome inventories will be assessed in two stages, ini-
tially together, and if significant they will be analysed
separately. Pre-treatment differences on continuous and
categorical demographic variables between the two treat-
ments will be assessed using the independent samples t
test and Fisher’s exact test, respectively. Other changes
and differences in continuous variables will be assessed
using the repeated and independent samples t test, and
Fisher’s exact test and McNemar’s test to determine pro-
portional differences between or within groups, respect-
ively. Repeated testing within the same domain will be
controlled for multiple testing using the Holm-Bonferroni
method [105].
Missing data will be handled within the hierarchical
linear model analyses. For analyses where this is not ap-
propriate, last observation carried forward (LOCF) will
be applied. For inventories, missing data will be replaced
by the mean, provided that no more than 20% of values/
item for this measure are missing. If more than 20% of
values/item are missing, data will be considered invalid,
and will be handled as missing as described. The poten-
tial impact of compliance with the different treatment
elements will be addressed in separate analyses.
Dissemination of results
We will submit results for publication in high impact,
open access, international peer-reviewed journals. We
will also communicate results through public media and
give lectures to relevant user groups, such as health care
practitioners in specialised health services, municipal
healthcare practitioners, low-threshold preventive mea-
sures and voluntary organisations.
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Discussion
Older adults are a rapidly increasing group. GAD is fre-
quent in this segment of the population, and older patients
with GAD often do not receive adequate and effective help
through the current healthcare systems, due to priorities
favouring younger adults or because of the absence of
proper healthcare programmes. Comorbid somatic and
psychiatric illnesses are common in GAD, and create a so-
cioeconomic burden [7]. Thus, it is also highly socioeco-
nomically relevant to develop effective treatment for older
adults. More importantly, effective treatment can lead to
an increase in quality of life for the individual suffering
from a psychiatric disorder, as well as improving comorbid
somatic disorders. As far as we know, the knowledge on
augmented treatment for older adults with GAD is scarce,
although previous studies have yielded promising findings.
As GAD is prevalent in older adults, and the impact of
treatment for this disorder seems reduced with age, it is
essential to develop more effective interventions for this
growing segment of our population. To the best of our
knowledge, no previous studies have investigated CBT aug-
mented with physical exercise in older adults with GAD.
The aim of the present study is to compare the effects
of CBT combined with either physical exercise or tele-
phone call attention placebo. We expect that partici-
pants receiving CBT + PE will have greater symptom
reduction assessed by the PSWQ than participants re-
ceiving CBT + AP. Further we expect physical exercise
to be an efficient add-on treatment strategy for older
adults with GAD because of the benefits of physical ex-
ercise on cognitive functions, mediated by changes in
BDNF and HRV. We do not expect telephone calls to
affect cognitive functions through these mediators, al-
though adding telephone calls to CBT might provide a
placebo effect. With the telephone calls, we try to con-
trol for the added human contact in the physical exercise
condition. The added attention could increase the par-
ticipants’ focus on the CBT, and as such enhance the
treatment efficacy. However, we take great care not to
focus on therapeutic content, and kindly ask the partici-
pant to discuss the therapy with their CBT therapist, if
they bring up CBT-related themes or questions. We also
instruct the physical exercise therapists to refer to the
CBT therapists for CBT-related question and themes.
In addition to expecting more symptom reduction on
the PSWQ in participants receiving CBT + PE, we also ex-
pect these participants to gain improved HRV and elevated
baseline and acute BDNF levels at the post-treatment and
follow-up measurements, as compared participants receiv-
ing CBT +AP. We will also explore whether these mea-
sures change over treatment in both treatment arms, and if
so, how this change evolves over the follow-up measures.
Furthermore, we expect CBT + PE to positively affect cog-
nitive functions as measured by our neuropsychological
test battery, as compared to CBT +AP. One potential limi-
tation to this approach is the learning effects in repeated
neuropsychological testing. We do expect learning effects,
especially with the Wisconsin Card Sorting Test, and the
California Verbal Learning Test. However, we control for
this by repeating the testing in both treatment conditions
and by comparing the groups.
The current study has both strengths and limitations
that should be noted. One of the strengths of this study
is the large number of tests and measures at multiple
time points. This allows for investigation of mediators of
treatment efficacy, which otherwise would be impossible
to measure. However, the number of tests and measures
could also pose more strain on participants, which might
increase the risk of drop-out at the post-treatment and
follow-up test points. We work actively to reduce this
risk by coordinating the tests and treatment closely, and
calling participants to schedule follow-up tests. By admin-
istering many questionnaires, we also have an increased
risk of missing data. We monitor this by being physically
present or available to participants as they complete the
questionnaires, which allows us to reduce the number of
missing responses.
With this study, we aim to fill some of the gaps in the
existing knowledge on GAD in older adults. The study
design allows us to investigate the effect of physical exer-
cise as an augmentation to CBT. We also investigate
long-term effects through follow up of the participants;
additionally, we include several measures that allow us
to examine both treatment effects and possible media-
tors and moderators of treatment outcome. Some im-
portant implications of this study will be to ensure
accurate and more available treatment programmes for
older adults.
Trial status
The study is registered on ClinicalTrials.gov (NCT02690441).
The Regional Ethical Committee has approved the
study, reference number 2015/2189, approved 2015.11.15.
The study opened for recruitment in September 2017, and
we plan to conclude data collection in December 2020.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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